Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...

Films like Strong: Living with Multiple Myeloma are essential. Multiple Myeloma is not exactly high on the list of diseases ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

The main focus right now in the myeloma paradigm of treatment is, okay, how do we harness the best power of CAR-T? We're doing it later in the treatment of myeloma. We've tried to move it earlier, and ...

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone or Rvd Plus ...

which showed that D-VRd led to significant improvement in PFS compared with VRd alone in patients with newly diagnosed multiple myeloma eligible for stem cell transplant, and led to the regimen's ...